Method of treating hypertension

Patent metadata

Field	Value
Publication number	US-2023030113-A1
Application number	US-202217950642-A
Country	US
Kind code	A1
Filing date	Sep 22, 2022
Priority date	Sep 8, 2017
Publication date	Feb 2, 2023
Grant date	—

Abstract

Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of Quetiapine or derivative thereof. The compositions include an effective amount of Quetiapine or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

First claim

1 - 14 . (canceled)

15 . A pharmaceutical composition comprising quetiapine or a pharmaceutically acceptable salt or ester thereof, and at least one additional agent effective to treat pulmonary hypertension.

16 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more of phosphodiesterase inhibitors, calcium channel blockers, endothelin receptor antagonists, inotropic agents, prostacyclin pathway agonists, anti-coagulants, guanylate cyclase stimulators, PDE-5 inhibitors, or a combination thereof.

17 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more of avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, icariin, amlodipine, nifefipine, diltiazem, bosentan, ambrisentan, sitaxsentan, macitentan, riociguat, toprimate, fusadil, warfarin, digoxin, epoprostenol, treprostinil sodium, iloprost, selexipag, or a combination thereof.

18 . A kit comprising quetiapine or a pharmaceutically acceptable salt or ester thereof, in an amount effective to treat pulmonary hypertension, and at least one additional agent effective to treat pulmonary hypertension.

19 . The kit of claim 18 , wherein the at least one additional agent comprises one or more of phosphodiesterase inhibitors, calcium channel blockers, endothelin receptor antagonists, inotropic agents, prostacyclin pathway agonists, anti-coagulants, guanylate cyclase stimulators, PDE-5 inhibitors, or a combination thereof.

20 . The kit of claim 18 , wherein the at least one additional agent comprises one or more of avanafil, lodenafil, mirodenafil, sildenafil, tadalafil, vardenafil, udenafil, zaprinast, icariin, amlodipine, nifefipine, diltiazem, bosentan, ambrisentan, sitaxsentan, macitentan, riociguat, toprimate, fusadil, warfarin, digoxin, epoprostenol, treprostinil sodium, iloprost, selexipag, or a combination thereof.

21 . The kit according to claim 18 , comprising a first composition comprising quetiapine or pharmaceutically acceptable salt or ester thereof, and a second composition comprising the at least one additional agent effective to treat pulmonary hypertension.

22 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more phosphodiesterase inhibitors.

23 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more calcium channel blockers.

24 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more endothelin receptor antagonists.

25 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more inotropic agents.

26 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more prostacyclin pathway agonists.

27 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more anti-coagulants.

28 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more guanylate cyclase stimulators.

29 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises one or more PDE-5 inhibitors.

30 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises sildenafil, tadalafil, or a combination thereof.

31 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises epoprostenol, iloprost, treprostinil sodium, or a combination thereof.

32 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises riociguat.

33 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises bosentan, macitentan, ambrisentan, sitaxsentan, or a combination thereof.

34 . The pharmaceutical composition of claim 15 , wherein the at least one additional agent comprises amlodipine, nifefipine, diltiazem, or a combination thereof.

Assignees

• Cipla Ltd

Inventors

• Malhotra Geena
• Joshi Kalpana
• Ghosalkar Jeevan

Classifications

• A61K31/554 Primary

  having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61K9/2054

  Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title